We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Age Alters Diagnostic Performance of Cardiac Troponin

By LabMedica International staff writers
Posted on 20 Sep 2022

The guideline-recommended thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups. More...

Relying on the sex-specific 99th percentile upper reference limit of cardiac troponin may incorrectly suggest myocardial infarction (MI) in older adults with suspected heart attacks, though no diagnostic approach has emerged as a better alternative.

Cardiovascular Scientists at the University of Edinburgh (Edinburgh, UK) and their colleagues assessed the diagnostic accuracy of high-sensitivity cardiac troponin I at presentation for the diagnosis of type 1, type 2, or type 4b myocardial infarction across three age groups (<50, 50–74, and ≥75 years) using guideline-recommended sex-specific and age-adjusted 99th centile thresholds. This was a secondary analysis of a multicenter trial across 10 hospitals in Scotland of consecutive patients with suspected myocardial infarction. The study included 46,435 consecutive patients aged 18 to 108 years (mean, 61±17 years), 5,216 (11%) had a diagnosis of myocardial infarction.

The team reported that thresholds for increased high-sensitivity cardiac troponin I (hs-cTnI), indicating myocardial injury and potential infarction, performed at a similar sensitivity around 80% in people across age groups. However, specificity for MI fell with increasing age: 98.3% in people under 50 years, 95.5% in those 50-74, and 82.6% in those age 75 and older. For that oldest group, age-adjusted 99th percentile thresholds improved specificity to 91.3% at the cost of a major loss in sensitivity (down from 81.6% to 55.9%) for an overall positive predictive value (PPV) of 59.3%. Other alternative hs-cTnI analyses they tried for people over 75 years old, applying a universal rule-in threshold of 64 ng/L, and factoring in the person's cardiovascular comorbidities, also failed to take MI diagnosis to an acceptable balance of sensitivity and specificity similar to that seen in younger patients.

Atul Anand, MD, PhD, a cardiovascular scientist and a lead author of the study, said, “No approach achieved parity in the diagnosis between older and younger patients with specificity and PPV reducing with advancing age regardless of the threshold adopted, and alternatives to the guideline-recommended approach resulted in a marked reduction in sensitivity in older persons.”

The authors concluded that age alters the diagnostic performance of cardiac troponin, with reduced specificity and positive predictive value in older patients when applying the guideline-recommended or age-adjusted 99th centiles. Individualized diagnostic approaches rather than the adjustment of binary thresholds are needed in an aging population. The study was published on September 15, 2022 in the journal Circulation.

Related Links:
University of Edinburgh


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Parainfluenza Virus Test
PARAINFLUENZA ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.